Cited by 327Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsBlood Pressure and Hypertension Studies

The DOI matches its Crossref record, with a small difference in title or year.

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk

Open access

Mach, Francois, Baigent, Colin, Catapano, Alberico L., Koskinas, Konstantinos C., Casula, Manuela, Badimon, Lina, Chapman, M. John, De Backer, Guy G., Delgado, Victoria, Ference, Brian A., Graham, Ian M., Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R., Riccardi, Gabriele, Richter, Dimitrios J., Sabatine, Marc S., Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov·2020·Russian Journal of Cardiology

DOI 10.15829/1560-4071-2020-3826

Open this paper in CoChat — free account

Abstract

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.15829/1560-4071-2020-3826

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Still being checked.

Sorted by citations

Items 101–200 of 327

Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories
Mizuta, H., Ishii, M., Ikebe, S., Otsuka, Y., Yamanouchi, Y., Nakamura, T., & Tsujita, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65334 · Cited by 8
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
Study, A. T. S. H. C., Courlet, P., Guidi, M., Saldanha, S. A., Stader, F., Traytel, A., Cavassini, M. L., Stoeckle, M. P., Buclin, T., Marzolini, C., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00946-3 · Cited by 7
Familial Hypercholesterolemia
Bagnasco, M. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96031 · Cited by 7
Macroalgae as a Source of Functional Foods in the Prevention of Cardiovascular Diseases
Valado, A., Ponedilok, P., Caseiro, A., & Pereira, L. (2023) · Recent Progress in Nutrition · doi:10.21926/rpn.2304024 · Cited by 6
Early, Intensive and Persistent Lipid-Lowering Therapy for Secondary Prevention of Acute Coronary Syndrome
Okada, K., Haze, T., Kikuchi, S., Kirigaya, H., Hanajima, Y., Tsutsumi, K., Kirigaya, J., Nakahashi, H., Gohbara, M., Kimura, Y., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64988 · Cited by 6
Cardiac microcalcification burden: Global assessment in high cardiovascular risk subjects with Na[18F]F PET-CT
Borges-Rosa, J., Santos, M. O., Silva, R., da Silva, N. P., Abrunhosa, A., Castelo-Branco, M. S., Gonçalves, L. M. M., & Ferreira, M. J. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02600-2 · Cited by 6
Current causes of death in familial hypercholesterolemia
Marco-Benedí, V., Bea, A. M., Cenarro, A., Jarauta, E., Laclaustra, M., & Civeira, F. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01671-5 · Cited by 8
DYSLIPIDEMIA AND SEVERITY OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND SUBCLINICAL HYPOTHYROIDISM
Петрова, Е. Б., Cardiology", M., Николаевна, Ш. О., Статкевич, Т. В., Плешко, А. А., & MITKOVSKAYA, N. P. (2022) · Avicenna Bulletin · doi:10.25005/2074-0581-2022-24-3-306-316 · Cited by 6
The Effects of Foods on Blood Lipids in Non-alcoholic Fatty Liver Disease (NAFLD)—A Systematic Review and Meta-Analysis
Rosqvist, F., Rydell, A., & Iggman, D. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.613221 · Cited by 6
Subfractional Spectrum of Serum Lipoproteins and Gut Microbiota Composition in Healthy Individuals
Kashtanova, D. A., Klimenko, N. S., Ткачева, О. Н., Strazhesko, I. D., Metelskaya, V. A., Gomyranova, N. V., & Boytsov, S. A. (2021) · Microorganisms · doi:10.3390/microorganisms9071461 · Cited by 7
Predictive effect of different blood lipid parameters combined with carotid intima-media thickness on coronary artery disease
Yu, B., Wu, Y., Li, W., Zhou, L., Lin, Y., Wang, W., Li, G., Zhou, Y., Hu, X., & Li, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1105413 · Cited by 6
Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report
Tanaka, A., Oyama, K., Yakushiji, Y., Natsuaki, M., Mizuno, A., Saito, Y., Matsumoto, S., Yamagami, H., Kunieda, T., Shibata, S., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65908 · Cited by 6
Roux-en-Y Gastric Bypass vs Vertical Sleeve Gastrectomy in the Remission of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Talledo, J. A., Caballero-Alvarado, J., Davila, M. D. L. C., & Zavaleta-Corvera, C. (2024) · Polish Journal of Surgery · doi:10.5604/01.3001.0054.2674 · Cited by 7
Role of pharmacists in the management of patients with obesity
Jovanović, M., Kovačević, M., & Ćulafić, M. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50561 · Cited by 6
Associations of body mass index and remnant cholesterol with hyperuricemia in patients with hypertension
Zhou, W., Wang, T., Zhu, L., Shi, Y., Yu, C., Bao, H., & Cheng, X. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01902-7 · Cited by 5
Global Low-Density Lipoprotein Cholesterol Targets for Patients With Acute Coronary Syndrome ― Current Guidelines and Clinical Pathways ―
Minami, Y., Ikari, Y., Harada, M., Suzuki, H., Fukui, K., Ako, J., Akashi, Y. J., Hibi, K., Kamioka, N., Koga, M., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0365 · Cited by 8
Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
Vavlukis, A., Vavlukis, M., Dimovski, A. J., Petrushevska, G., Eftimov, A., Domazetovska, S., & Mladenovska, K. (2021) · Acta Pharmaceutica · doi:10.2478/acph-2022-0018 · Cited by 5
Experience in using the results of periodic medical examinations to assess the risk of developing diseases of the circulatory system
Габдрахмановна, Г. В., Сергеевич, Ш. А., Dubenko, S. E., Kurbanova, N. A., Mazhaeva, T. V., Михайловна, Ц. Т., & Ruzakov, V. O. (2022) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20222505161 · Cited by 5
A urinary peptidomics approach for early stages of cardiovascular disease risk: The African-PREDICT study
de Beer, D., Mels, C. M. C., Schutte, A. E., Delles, C., Mary, S., Mullen, W., Mischak, H., & Kruger, R. (2022) · Hypertension Research · doi:10.1038/s41440-022-01097-7 · Cited by 5
Gaps in the Care of Subjects with Familial Hypercholesterolemia: Insights from the Thai Familial Hypercholesterolemia Registry
Ganokroj, P., Muanpetch, S., Deerochanawong, C., Phimphilai, M., Leelawattana, R., Thongtang, N., Krittayaphong, R., Anthanont, P., Vathesatogkit, P., Sriphrapradang, C., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64081 · Cited by 5
Acute ischemic stroke in tuberculous meningitis
Guo, Y., Gan, X.-L., Zhang, R.-Y., Liu, Y., Wang, E.-L., Lu, S., Jiang, H., Duan, H.-F., Yuan, Z., & Li, W. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1362465 · Cited by 5
Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review
Biswas, K., Tiwari, A., Jadhav, P., Goel, A., & Chanukya, G. V. (2021) · Journal of Current Medical Research and Opinion · doi:10.15520/jcmro.v4i03.405 · Cited by 5
Visual Scale as a Non-Invasive Method for Evaluation of Risk and Severity of Coronary Atherosclerosis
Zhatkina, M. V., Гаврилова, Н. Е., Metelskaya, V. A., Yarovaya, E. B., Руденко, Б. А., & Drapkina, O. M. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1481 · Cited by 5
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction
Cao, Y., Li, S., Liu, H., Zhang, M., Guo, Y., Wu, N., Zhu, C., Dong, Q., Sun, J., Dou, K., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.797297 · Cited by 5
The GenoDiabMar Registry: A Collaborative Research Platform of Type 2 Diabetes Patients
Sierra, A., Otero, S., Rodríguez, E., Faura, A., Vera, M., Riera, M., Palau, V., Durán, X., Costa-Garrido, A., Sans, L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051431 · Cited by 5
Intelligent digitalization of cardiovascular risks
Gromov, Y. Y., Gorbunov, A. V., & Tyutyunnik, V. M. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.22.7794 · Cited by 5
Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment
Yamaji, T., Harada, T., Kajikawa, M., Maruhashi, T., Kishimoto, S., Yusoff, F. M., Chayama, K., Goto, C., Nakashima, A., Tomiyama, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64416 · Cited by 5
Dislipidemia diabética
Parcero-Valdés, J. J. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100791 · Cited by 5
Multilevel Factors Predict Medication Adherence and Efficacy within 12 Months in Patients Receiving PCSK9 Monoclonal Antibodies: The Findings from a Real-World Analysis in China
Zheng, X., Jin, Y., Fan, M., Cui, H., & Zhu, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65624 · Cited by 4
Primary Prevention of Cardiovascular Risk in Lithuania—Results from EUROASPIRE V Survey
Urbonas, G., Vencevičienė, L., Valius, L., Krivickienė, I., Petrauskas, L., Lazarenkienė, G., Karpavičienė, J., Briedė, G., Žučenkienė, E., & Vencevičius, K. (2020) · Medicina · doi:10.3390/medicina56030134 · Cited by 4
Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study
Chun, K., Park, J. M., Lee, C. J., Oh, J., Park, S., Kang, S., & Lee, S.-H. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63004 · Cited by 4
Determination of the Optimal Cutoff Value of Triglyceride That Corresponds to Fasting Levels in Chinese Subjects With Marked Hypertriglyceridemia
Guo, L., Zhu, L., Xu, J. R., Xie, Y., Xiang, Q., Jiang, Z.-Y., Tan, Y., & Liu, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.736059 · Cited by 4
Association between statin use and the prognosis of patients with acute myocardial infarction complicated with diabetes
Lu, X., Zhang, L., Li, S., He, D., Huang, T., Lin, H., Yin, H., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.976656 · Cited by 4
Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease
Qu, Y., Yh, S., Sun, R., Ma, Y., & Zhang, Y. (2024) · Physiological Research · doi:10.33549/physiolres.935164 · Cited by 4
Stable Ischemic Heart Disease
Fahed, A. C., & Chae, C. U. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_6 · Cited by 4
Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral Artery Disease
Iida, O., Takahara, M., & Mano, T. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17058 · Cited by 4
Tratamiento actual de la hipertrigliceridemia
Álvarez‐López, H., Ruiz-Gastélum, E., & Díaz-Aragón, A. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100805 · Cited by 4
PCSK9 inhibitors: role in reducing cardiovascular diseases
Malyarevskaya, O. V., Муратович, Н. А., Кручинова, С. В., & Kosmacheva, E. D. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-2-32-40 · Cited by 5
Factors to consider with estimated low-density lipoprotein cholesterol using the new Sampson/NIH equation
Logan, S. M., & Selvaratnam, R. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110633 · Cited by 4
Coronary Artery Disease: Optimal Lipoprotein(a) for Survival—Lower Is Better? A Large Cohort With 43,647 Patients
Liu, J., Liu, L., Wang, B., Chen, S., Liu, B., Liang, J., Huang, H., Li, Q., Lun, Z., Ying, M., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.670859 · Cited by 4
Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients
Yao, Y., Liu, J., Wang, B., Zhou, Z., Lu, X., Huang, Z., Deng, J., Yang, Y., Tan, N., Chen, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.817442 · Cited by 4
Influence of inflammation on lipid profile in chronic rheumatic diseases
Shilova, L. N., & Сергеевна, С. С. (2023) · Medical alphabet · doi:10.33667/2078-5631-2023-9-64-69 · Cited by 4
Metabolic Risk Factors and Their Impact on Quality of Life in Patients with Pancreatic Cancer, Acute or Exacerbated Chronic Pancreatitis
Григорьева, И. Н., Efimova, O., Тов, Н. Л., Станиславовна, С. Т., & Nepomnyashchikh, D. L. (2023) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2023-33-3-49-60 · Cited by 3
Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
Zhang, S., Li, Z.-F., Shi, H.-W., Zhang, W., Sui, Y., Li, J., Dou, K., Qian, J., & Wu, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.859567 · Cited by 4
Association of hypertriglyceridemia with risk factors for cardiovascular and renal complications in individuals with high cardiovascular risk
Murkamilov, I. T., Fomin, V. V., Абдилалимовна, М. Ж., Sabirov, I. S., Ибрагимовна, С. А., Умурзаков, Ш. Э., Yusupov, F. A., Maanaev, T. I. M., & Gassanov, K. A. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5215 · Cited by 3
CLINICAL AND LABORATORY PARALLELS OF CYSTATIN C AND LIPID METABOLISM PARAMETERS IN PERSONS WITH HIGH CARDIOVASCULAR RISK
(2023) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2023-68-1-23-31 · Cited by 3
Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy
Lippi, G., & Targher, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0076 · Cited by 3
Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome
Bruckert, É., Désaméricq, G., Khachatryan, A., Ngo, P., Gusto, G., & Sorio-Vilela, F. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.04.189 · Cited by 4
A new milestone on the road to global standardization of apolipoprotein measurements
Langlois, M. R. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1117 · Cited by 3
INCLISIRAN - A NEW SOLUTION FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Lis, P., Lis, A. E., Kaźmierski, W., Jurek, J., Ziomek, M., Kocur, K., Ziobro, A., & Camlet, K. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.241 · Cited by 3
Comparative Effectiveness and Safety of Moderate-Intensity Pravastatin Versus Atorvastatin in Patients with Dyslipidemia: A Retrospective Cohort Study Using a Common Data Model of Multicenter Electronic Health Records in South Korea
Chun, S. W., Kim, H. J., Seo, J. A., Chon, S., Kim, S. E., Jung, J. H., Kim, S. S., Lee, H., Shin, S., Kim, S. H., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65345 · Cited by 2
Predictive Value of Lipoprotein(a) Combined with the Suita Score for High-Risk Plaque in Japanese Patients
Niwa, Y., Naruse, H., Kawai, H. D., Sakaguchi, E., Ishihara, Y., Hattori, H., Uehara, K., Ito, M., Yamada, S., Yamada, A., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65904 · Cited by 2
Genetic Testing for Children with Familial Hypercholesterolemia
Nagahara, K., Tada, H., & Dobashi, K. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22046 · Cited by 2
Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia
Balkrishna, A., Agarwal, U., Saxena, S., Sharma, G., & Arya, V. (2026) · Current Medical Science · doi:10.1007/s11596-025-00149-6 · Cited by 2
The association between remnant cholesterol and cardiovascular events: A systematic review and meta-regression
Byrne, P., Lin, T., Jones, M., Demasi, M., Saif-Ur-Rahman, K., & DuBroff, R. J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.026 · Cited by 2
Lipoprotein(a) Is Associated with Coronary Plaque Vulnerability and Compensatory Vascular Enlargement: An Intravascular Ultrasound Study
Jiang, Y., Lin, J., Ma, M., Xu, J., Yu, P., & Wang, H. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66159 · Cited by 2
Experience of using telmisartan, atorvastatin and ursodeoxycholic acid in patients with arterial hypertension in combination with non-alcoholic fatty liver disease
Efremova, O. A., Chernobai, P. Y., & Погурельская, Е. П. (2021) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20210510 · Cited by 2
Opinions of cardiologists on class II recommendations in current European Society of Cardiology 2018-2020 guidelines: YELLOW BOX
Kış, M., Güzel, T., Ekici, B., & Zoghi, M. (2022) · The European Research Journal · doi:10.18621/eurj.981861 · Cited by 2
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
Sudano, I., Mach, F., Moccetti, T., Burkard, T., Fahe, C., Delabays, A., Rickli, H., Keller, P., Dopheide, J. F., Bodenmann, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.953040 · Cited by 2
Self-citation
Combined impacts of low apolipoprotein A-I levels and reduced renal function on long-term prognosis in patients with coronary artery disease undergoing percutaneous coronary intervention
Fukase, T., Dohi, T., Nishio, R., Takeuchi, M., Takahashi, N., Chikata, Y., Endo, H., Doi, S., Nishiyama, H., Okai, I., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.09.020 · Cited by 2
New opportunities for identifying the risk of cardiovascular events in young people: the role of familial hypercholesterolemia
Emelyanchik, V. S., Nikulina, S. Y., Emelyanchik, E. Y., & Protopopov, A. V. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5294 · Cited by 5
Внезапная сердечная смерть у молодых мужчин: результаты экзомного секвенирования
Ivanova, A. A., Иванощук, Д. Е., Orlov, P. S., Родина, И. А., Хамович, О. В., Malyutina, S. K., Novoselov, V. P., & Максимов, В. Н. (2023) · Ateroscleroz · doi:10.52727/2078-256x-2022-18-4-317-337 · Cited by 2
Omega-3 polyunsaturated fatty acids for the management of dyslipidemia and reduction of residual cardiovascular risk
Kytikovа, O. Y., Novgorodtseva, T. P., Denisenko, Y., Antonyuk, M. V., & Gvozdenko, T. A. (2023) · Bulletin physiology and pathology of respiration · doi:10.36604/1998-5029-2023-87-124-137 · Cited by 3
Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage
Larina, V. N., Mironova, T. N., Геннадьевич, Л. В., Makhova, U. V., Orlov, D. A., Varlamova, Y. Y., & Валерьевна, К. О. (2023) · Kardiologiia · doi:10.18087/cardio.2023.4.n2396 · Cited by 2
Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus
Kim, J. Y., Choi, J., Kim, S. G., & Kim, N. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0217 · Cited by 2
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
Vavlukis, A., Mladenovska, K., Davalieva, K., Vavlukis, M., & Dimovski, A. J. (2023) · Acta Pharmaceutica · doi:10.2478/acph-2023-0034 · Cited by 2
Performance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study
Yu, S., Sun, H. Y., & Yoo, B. W. (2023) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2023.00528 · Cited by 2
Determining cost-saving risk thresholds for statin use
Gandjour, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318454 · Cited by 2
Prospective study on breastfeeding, lipid profile and cardiovascular risk markers in women with familial hypercholesterolaemia: study protocol for the FH-FEMINA study
Klevmoen, M., Mulder, J. W. C. M., Bogsrud, M. P., Retterstøl, K., Vesterbekkmo, E. K., Pedersen, E. K. R., Freiberger, T., Vrablı́k, M., Vaclová, M., Hovland, A., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-092208 · Cited by 2
Long-Term Exposure to High Low-Density Lipoprotein Cholesterol Levels and Clinical Course in Secondary Prevention After Coronary Artery Disease
Matsumoto, I., Mukaida, K., Wada, K., Kurozumi, M., Namba, T., & Takagi, Y. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0091 · Cited by 4
Pathogenetic rationale for using an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and an antioxidant coenzyme Q10 in the treatment and prevention of cardiovascular disease
Дзугкоев, С. Г., Garmash, O. Y., & Дзугкоева, Ф. С. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2793 · Cited by 3
Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
Chua, Y.-A., Nazli, S. A., Rosman, A., Kasim, S. S., Ibrahim, K. S., Radzi, A. B. M., Kasim, N. A. M., & Nawawi, H. M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63389 · Cited by 2
Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek *
Maligłówka, M., Bułdak, Ł., Okopień, B., & Bołdys, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.9127 · Cited by 2
Mild Malnutrition Contributes the Greatest to the Poor Prognosis in Coronary Artery Disease With Well-Controlled Low-Density Lipoprotein Cholesterol Levels: A 4,863 Chinese Cohort Study
Wang, B., Guo, Z.-D., Liu, J., Li, H.-Q., Mai, Z.-L., Lin, F., Ying, M., Yu, Y., Chen, S., Li, Q., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.725537 · Cited by 2
Assessment of the global and national market for lipid modifying agents: retrospective and innovation
Валерьевна, Л. А., Геннадьевна, Ф. С., Trubina, L. V., & Sikhvardt, I. E. (2023) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20230403 · Cited by 3
Joint Association of Lipoprotein(a) and a Family History of Coronary Artery Disease with the Cardiovascular Outcomes in Patients with Chronic Coronary Syndrome
Liu, H., Li, S., Zhang, Y., Guo, Y., Zhu, C., Wu, N., Gao, Y., Xu, R., Dong, Q., & Li, J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64693 · Cited by 2
Statin Utilization among Patients with Acute Coronary Syndrome: Systematic Review
Dewi, P. E. N., & Thavorncharoensap, M. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.5807 · Cited by 1
Acercamiento a los síndromes de hipertrigliceridemia: la importancia de distinguir entre etiologías primaria y secundaria
Cruz‐Bautista, I. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100804 · Cited by 1
Analysis of lipid-lowering therapy depending on socio-demographic factors in primary health care: data from the ARGO study
Safaryan, A. S., & Vygodin, V. A. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3445 · Cited by 1
Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review
Larina, V. N., Геннадиевна, Г. М., Геннадьевич, Л. В., Mironovna, T. N., & Orlov, D. A. (2023) · Cardiosomatics · doi:10.17816/cs133705 · Cited by 1
GENDER DIFFERENCES IN FAMILIAL HYPERCHOLESTEROLEMIA
Opalinskaya, I. V., Исааковна, Б. Е., Babokin, V. E., Vasilieva, N. P., Fedorova, S. S., & Stepanova, E. Р. (2023) · Acta medica Eurasica · doi:10.47026/2413-4864-2023-2-14-22 · Cited by 1
HYPERTRIGLYCERIDEMIA AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASES
NURIEVA, L. M., KIM, Z. F., GALYVICH, A. S., & Sadykova, D. I. (2023) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2023.16(4).104-110 · Cited by 1
Relationships of Fat Mass Index and Fat-Free Mass Index with Low-Density Lipoprotein Cholesterol Levels in the Tohoku Medical Megabank Community-Based Cohort Study
Takase, M., Nakamura, T., Nakaya, N., Kogure, M., Hatanaka, R., Nakaya, K., Chiba, I., Kanno, I., Nochioka, K., Tsuchiya, N., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64535 · Cited by 1
Risk of Hemorrhagic Stroke among Patients Treated with High-Intensity Statins versus Pitavastatin-Ezetimibe: A Population Based Study
Chen, P.-S., Lin, J., Lin, H., Lin, S., & Li, Y. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j019 · Cited by 1
Non-high-density lipoproteins cholesterol and cardiometabolic diseases
Каширина, А. П., & Симонова, Г. И. (2024) · Ateroscleroz · doi:10.52727/2078-256x-2024-20-2-183-194 · Cited by 1
Seasonality of Atherosclerotic Cardiovascular Disease: Role of Natural and Anthropogenic Factors
Churilov, L. P., Gurevich, V. S., Сергеевич, С. П., Soprun, L. A., & Stroev, Y. I. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-62806-1_3 · Cited by 1
Using mathematical models in the assessment of the circulatory system in employees working under harmful occupational conditions
Габдрахмановна, Г. В., Сергеевич, Ш. А., Васильевна, Ч. Д., Даниловна, К. Е., Maslakova, T. A., Юрьевна, О. С., Вараксин, А. Н., & Bortsov, S. M. (2024) · Hygiene and Sanitation · doi:10.47470/0016-9900-2024-103-9-947-953 · Cited by 1
Impact of a Physician-led Strike Early–Strike Strong Lipid-Lowering Protocol Incorporating PCSK9 Inhibitors for Patients with Acute Myocardial Infarction
Arai, R., Hotsubo, Y., Nakajima, Y., Sumida, R., Mizobuchi, S., Migita, S., Tanaka, Y., Hori, K., Fukumoto, K., Ebuchi, Y., et al. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65731 · Cited by 1
Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Physician and patient perspectives on the treatment of hypercholesterolaemia: a cross-sectional study to identify disconnects
Viljoen, A., Auyeung, V., Foot, H., Grimmett, C., Bodini, S., Douglas, L., Kaloti, T., Moon, Z., Chhabra, R., Cotterill, E., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2538748 · Cited by 1
Self-citation
The effect of follow-up reexamination on the long-term prognosis of patients with acute coronary syndrome undergoing coronary angiography
Wang, C., Cui, L., Ma, X., Sun, M., Wang, Y., Dong, F., Zhao, C., Tian, X., Wang, Y., Zhang, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04346-x · Cited by 1
Diseases of the circulatory system and life expectancy of men in an industrial region
Кorotenko, O. Y., & Baran, O. I. (2025) · Hygiene and Sanitation · doi:10.47470/0016-9900-2025-104-7-818-825 · Cited by 1
Comparison of the Friedewald, Martin/Hopkins, and Sampson Equations for Calculating Low-Density Lipoprotein Cholesterol
Hataysal, E. P., & Saraçlıgil, B. (2025) · Genel Tıp Dergisi · doi:10.54005/geneltip.1670413 · Cited by 1
Up-regulation of intra-tumour LDLR gene expression is associated with statin treatment and better prostate cancer prognosis
Fonfara, K. E., Fredsøe, J., Ulhøi, B. P., Borgquist, S., Borre, M., & Sørensen, K. D. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.43788 · Cited by 1
Associations of non-high-density lipoprotein cholesterol with the prevalence and risk of type 2 diabetes mellitus in an urban siberian population
Симонова, Г. И., Щербакова, Л. В., Каширина, А. П., & Malyutina, S. K. (2026) · Ateroscleroz · doi:10.52727/2078-256x-2026-22-1-41-59 · Cited by 1
Cardiometabolic profile and characteristics of lipid-lowering therapy in liver transplant recipients in the practice of a cardiologist
Кучеров, А. А., Ershova, A. I., Novokhatskaya, E. A., Евгеньевич, С. В., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4776 · Cited by 1
Harmonization of Lipoprotein(a) Immunoassays with the IFCC- Endorsed Reference Measurement Procedure Validated in Patient Samples and Multiple Routine testing as A Second Step Towards Apolipoprotein Standardization
Yamashita, K., Wakita, M., Niizeki, N., Ito, S., Ito, Y., 佐藤, 麻., Miura, H., Yoshida, H., Masaki, T., Matsushita, K., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66345 · Cited by 1
Hypertriglyceridemia is associated with long-term risk of cardiovascular events and specific comorbidity in very high-risk hypertensive patients
Korolyuk, O. Y., & Radchenko, О. М. (2020) · The Ukrainian Biochemical Journal · doi:10.15407/ubj92.02.008 · Cited by 1
New approach for the rehabilitation of patients with chronic heart failure associated with type 2 diabetes
Николаевна, С. М., Константинович, И. Л., Синьков, М. А., Plotnikova, E. Y., & Гуляева, Е. Н. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-14-40-47 · Cited by 1
Dislipidemia en la mujer, una revisión actual basada en el riesgo cardiovascular
Ancona-Vadillo, A. E. (2021) · Cardiovascular and Metabolic Science · doi:10.35366/100798 · Cited by 1

Authors: Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M.-R., Tokgozoglu, L., & Wiklund, O.
Affiliations: Geneva University Hospital
University of Oxford (GB)
University of Milan (IT)
ORCID: Baigent, Colin
Catapano, Alberico L.
Koskinas, Konstantinos C.
Casula, Manuela
Chapman, M. John
Delgado, Victoria
Halliday, Alison
Landmesser, Ulf
Mihaylova, Borislava
Pedersen, Terje R.
Richter, Dimitrios J.
Sabatine, Marc S.
Taskinen, Marja-Riitta
Wiklund, Olov
Venue: Russian Journal of Cardiology
Publisher: Silicea - Poligraf, LLC
Published: 2020-06-08
Volume: 25
Issue: 5
Pages: 3826
ISSN: 1560-4071 (ISSN-L)
2618-7620
DOI: 10.15829/1560-4071-2020-3826
OpenAlex: W3034853614
Cited by: 325
References: 0
Citations by year: 2026: 28 · 2025: 39 · 2024: 37 · 2023: 62 · 2022: 56 · 2021: 70 · 2020: 25
FWCI: 48.66
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by
russjcardiol.elpub.ru/jour/about/editorialPolicies#openAccessPolicy (vor)
Locations: Russian Journal of Cardiology (publishedVersion, cc-by)
Russian Cardiology Journal (Russian Cardiology Society) (submittedVersion, cc-by)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: dyslipidemia, lipid modification, cardiovascular risk reduction, dyslipidemia management, ESC/EAS guidelines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks